Proizvod vam ne odgovara? Nema veze! Možete nam vratiti unutar 30 dana
S poklon bonom ne možete pogriješiti. Za poklon bon primatelj može odabrati bilo što iz naše ponude.
30 dana za povrat kupljenih proizvoda
Health care costs are on the rise in Australia. Rational decisions using cost-effectiveness analyses are necessary to prioritise health interventions for the allocation of limited resources. Immunisation is an important component of preventive health care intervention and its cost-effectiveness analyses are useful in prioritising the choices. This book describes economic evaluation of two immunisation interventions in Australia: influenza and hepatitis B. We have analysed cost-effectiveness of reducing universal influenza vaccination age threshold to 50 from the current 65 using a decision tree model and cost-effectiveness of various hepatitis B infant vaccination strategies using a micro-simulation model. Here we describe the strength of the evidence to reduce universal influenza vaccination age threshold. Our results also suggest that the current hepatitis B vaccination strategy in Australia is an expensive one, but yields maximum health gain in general population. Is that the best choice? How good is Australian hepatitis B immunization strategy for indigenous population? Do we have alternative cost-effective choices? This book tries to explore all these questions.